title: [Adjuvant chemotherapy for patients with rectal cancer].
abstract: A new Cochrane meta-analysis evaluated adjuvant chemotherapy (5-fluorouracil (5FU)-based, not modern combination chemotherapy) in almost 10,000 patients with rectal cancer and showed a 17% reduction in mortality corresponding well to the efficacy observed in recent studies, which reported a reduction in mortality just about 20%. The authors recommend adjuvant chemotherapy which is in accordance with the Danish national guidelines where 5-FU-based chemotherapy is recommended for stage III and high-risk stage II rectal cancer.
authors.affiliation: Onkologisk Afdeling R, Odense Universitetshospital, Sdr. Boulevard 29, 5000 Odense C. camilla.qvortrup@ouh.regionsyddanmark.dk.
authors.forename: Camilla
authors.initials: C
authors.lastname: Qvortrup
authors.forename: John Pløen
authors.initials: JP
authors.lastname: Mortensen
authors.forename: Per
authors.initials: P
authors.lastname: Pfeiffer
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008279:Magnetic Resonance Imaging; D011184:Postoperative Period; D012004:Rectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012196:Review Literature as Topic
chemical_list: D000970:Antineoplastic Agents; D005472:Fluorouracil